www.stirlingproducts.net
Stirling Products (ASX:STI) is a manufacturer and marketer of proprietary and/or patented pharmaceutical products and natural health products for its own interests as well as on a contractual basis for third parties. Strategically, Stirling Products is positioned to capitalise on the rapidly changing conditions within the global pharmaceutical and health markets.
The Stirling Products corporate headquarters are in Sydney, Australia and its North American pharmaceutical manufacturing operations are based on Cape Breton, Nova Scotia, Canada.
Stirling operates through three main business units each managed by proven industry specialist managers:
- Pharmaceutical & Healthcare
- Research & Development
- Animal Products
Stirling Products appoints former Pfizer director as CEO
Stirling Products (ASX: STI) has appointed a new chief executive officer and consultant to the company.
Jeremy Cocks, Stirling’s new incoming chief executive offer, has previously held positions as a Director of Pfizer (NYSE: PFE) a US$163 billion valued company where he headed new products marketing and business development. He was recently Head of Marketing and Technical Services at Novartis (NYSE: NVS), valued at US$157 billion.
Cocks has expertise in the pharmaceutical animal health sector and has proven sales, marketing and management experience in Australia, the US and the UK.
The appointment will be formalised by 6 June 2011 and remains subject to a probationary term of three months and Board approval.
The company has also appointed John Botten to act as an advisor and consultant to Stirling.
Botten will advise and assist the company in the global commercialisation of its TeleMedCare e – Health vital signs monitoring business.
He has multi-national experience including 31 years at IBM (NYSE: IBM) and acted as Director at the computer hardware giant for 12 year including four years at IBM's European Headquarters in France as the Product Director resposible for the marketing of IBM's large systems across EMEA.
Botten also spent six years on the Board of the UK Forensic Science Service and is currently chairman of The Learning Machine, an open source education technology company.
Stirling has entered advanced stages of discussion with a UK broker and institutions regarding the potential dual listing of the company on the London Stock Exchange Alternative Investment Market, and subject to this, Botten has offered his services as a UK independent director.
Peter Boonen, managing director, said “Stirling is indeed fortunate to have the opportunity of securing the services of a new CEO who has proven management skills within the industry and can lead the company in the next phase of business development.”


















